Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Cancer treatment decisions are increasingly guided by which specific genes are mutated
within each patient's tumor. For example, agents inhibiting the epidermal growth factor …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …

Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in
cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins …

Recent clinical development of KRAS inhibitors has heightened interest in the genomic
landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered …

KRAS mutations are among the most common drivers of human carcinogenesis, and are
associated with poor prognosis and an aggressive disease course. With the advent of …

A number of studies have shown that although antiepidermal growth factor receptor (EGFR)
monoclonal antibodies are effective treatments for metastatic colorectal cancer (mCRC) …

Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down: Cancer Cell Skip
to Main Content Advertisement Cancer Cell This journal offers authors two options (open access …

Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the
development of effective targeted therapies directed against RAS has lagged behind those …